RTW INVESTMENTS, LP - ARBUTUS BIOPHARMA CORP ownership

ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 117 filers reported holding ARBUTUS BIOPHARMA CORP in Q1 2022. The put-call ratio across all filers is 1.37 and the average weighting 0.1%.

Quarter-by-quarter ownership
RTW INVESTMENTS, LP ownership history of ARBUTUS BIOPHARMA CORP
ValueSharesWeighting
Q4 2021$9,742,000
-52.0%
2,504,493
-47.1%
0.14%
-53.6%
Q3 2021$20,306,000
+12.1%
4,733,323
-20.8%
0.31%
+12.1%
Q2 2021$18,114,000
-9.0%
5,978,3550.0%0.27%
-12.2%
Q1 2021$19,908,000
-6.2%
5,978,3550.0%0.31%
-12.6%
Q4 2020$21,223,000
+13.4%
5,978,3550.0%0.36%
-21.1%
Q3 2020$18,712,000
+49.7%
5,978,355
-13.0%
0.45%
+28.1%
Q2 2020$12,502,000
+80.2%
6,869,2810.0%0.35%
+17.7%
Q1 2020$6,938,000
-56.0%
6,869,281
+21.2%
0.30%
-49.7%
Q4 2019$15,754,000
+85.7%
5,666,754
+1.9%
0.59%
+17.6%
Q3 2019$8,484,000
-26.3%
5,562,967
+0.5%
0.50%
-17.9%
Q2 2019$11,509,000
-41.7%
5,533,093
+0.4%
0.62%
-54.3%
Q1 2019$19,727,000
+18.8%
5,510,223
+27.1%
1.35%
-12.9%
Q4 2018$16,606,000
-57.0%
4,335,746
+6.1%
1.55%
-33.1%
Q3 2018$38,602,000
+2.4%
4,084,904
-20.9%
2.31%
-15.0%
Q2 2018$37,708,000
+46.4%
5,165,499
+0.3%
2.72%
+11.0%
Q1 2018$25,758,000
-1.0%
5,151,6150.0%2.45%
-43.6%
Q4 2017$26,016,000
-20.3%
5,151,615
-2.2%
4.34%
-23.6%
Q3 2017$32,651,000
+74.1%
5,266,280
+1.1%
5.69%
+43.8%
Q2 2017$18,755,000
+299.0%
5,209,823
+260.1%
3.95%
+219.6%
Q1 2017$4,701,0001,446,5871.24%
Other shareholders
ARBUTUS BIOPHARMA CORP shareholders Q1 2022
NameSharesValueWeighting ↓
Whitefort Capital Management, LP 11,895,477$24,147,81812.66%
Two Seas Capital LP 8,280,818$16,810,0613.38%
FourWorld Capital Management LLC 1,341,907$2,724,0710.51%
Tejara Capital Ltd 180,077$365,5560.21%
Woodline Partners LP 4,719,903$9,581,4030.11%
Hudson Bay Capital Management LP 8,299,808$16,848,6100.07%
Kepos Capital LP 155,691$3160.06%
Virtus ETF Advisers LLC 40,040$81,2810.05%
Centiva Capital, LP 1,071,705$2,175,5610.05%
Kades & Cheifetz LLC 20,000$40,6000.03%
View complete list of ARBUTUS BIOPHARMA CORP shareholders